Skip to main content
Quest Diagnostics

Elevated Serum Per- and Polyfluoroalkyl Substances (PFAS) Concentrations Associated with Public Drinking Water Contamination and Correlating Study between PFAS and Clinical Indicators in a Large Clinical Patient Cohort

National PFAS Conference 2026

Tuscon, AZ, June 8-10, 2026

Poster presentation: Elevated Serum Per- and Polyfluoroalkyl Substances (PFAS) Concentrations Associated with Public Drinking Water Contamination and Correlating Study between PFAS and Clinical Indicators in a Large Clinical Patient Cohort

Authors: Dui W, Smith M, Chen Z, Van K, Bare L, Swanson B, Kocur S, Kain J, Bartock S

Medical Specialty: Toxicology, Prescription Drug Monitoring

Related content

Publication
Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM)
Conference Presentation
Correlation Between PFAS Forever Chemical Concentrations in Remnant Serum and Public Drinking Water
Audio Podcast
PFAS: Understanding the Risks and the Role of Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.